AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · Real-Time Price · USD
0.1200
-0.0100 (-7.69%)
At close: Mar 28, 2025, 4:00 PM
0.1279
+0.0079 (6.58%)
After-hours: Mar 28, 2025, 7:48 PM EST
AIM ImmunoTech Employees
As of December 31, 2023, AIM ImmunoTech had 28 total employees, including 26 full-time and 2 part-time employees. The number of employees increased by 4 or 16.67% compared to the previous year.
Employees
28
Change (1Y)
4
Growth (1Y)
16.67%
Revenue / Employee
$6,071
Profits / Employee
-$618,571
Market Cap
7.65M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AIM News
- 2 days ago - Aimia Inc. (AIMFF) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 19 days ago - AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewsWire
- 4 weeks ago - AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza - GlobeNewsWire
- 4 weeks ago - AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance - GlobeNewsWire
- 4 weeks ago - AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director - GlobeNewsWire
- 4 weeks ago - AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer - GlobeNewsWire
- 6 weeks ago - AIM ImmunoTech Releases Virtual Investor “What This Means Segment” - GlobeNewsWire
- 6 weeks ago - AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 - GlobeNewsWire